Trial Profile

An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week in Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alogliptin (Primary) ; Trelagliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms TRACK
Sponsors Takeda

Most Recent Events

27 Sep 2019 Results assessing the effect of trelagliptin and alogliptin on glycemic variability in patients with type 2 diabetes published in the Advances in Therapy
01 May 2017 Status changed from active, no longer recruiting to completed.
26 Apr 2017 Planned number of patients changed from 30 to 27.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com